ReviewFrontiers in oncology2023

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.

Bryan Oronsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.